header image

Posts under ‘Merck’

MicroDose Therapeutx Announces Expansion of Collaboration with Merck & Co., Inc for Dry Powder Inhaler Technology

MONMOUTH JUNCTION, N.J. USA-July 22, 2009– MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that Merck & Co., Inc., through an affiliate, has exercised an option to extend its license to the MicroDose Dry Powder Inhaler (DPI) technology to an additional investigational compound.  This option originates from the previously announced collaboration agreement between the two companies and triggers the payment of an undisclosed exercise fee to MicroDose.

Under the terms of the collaboration agreement, Merck funds costs of development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds.  MicroDose is eligible to receive milestone payments and royalties on revenues from all products developed under the agreement.

MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.

MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose’s dry powder inhaler (DPI) technology announced in March 2008.

MicroDose Technologies Grants Global License to Merck & Co., Inc., for Use of the MicroDose Inhaler with Merck’s Proprietary Products

MONMOUTH JUNCTION, N.J., March 3 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) today announced that it has entered into a global license agreement with Merck & Co., Inc., through an affiliate, for use of MicroDose’s proprietary dry powder inhaler (DPI) with Merck compounds. This agreement follows the successful completion of an exploratory study evaluating the MicroDose DPI technology.